Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07091617 · ClinicalTrials.gov registry record · NA
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
A NA study of Miscellaneous Neoplasm, NOS and Non-Neoplastic Condition, Nos, sponsored by Alliance for Clinical Trials in Oncology.
- Recruiting
- Registry status
- NA
- Development phase
- 535
- Enrollment target
- 20
- Study locations
NCT07091617: Recruiting NA study of Miscellaneous Neoplasm, NOS and Non-Neoplastic Condition, Nos, sponsored by Alliance for Clinical Trials in Oncology.
NCT07091617 is a NA study of Miscellaneous Neoplasm, NOS and Non-Neoplastic Condition, Nos that is actively recruiting participants, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 535 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (62% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07091617, a NA study of Miscellaneous Neoplasm, NOS and Non-Neoplastic Condition, Nos, is actively recruiting participants, sponsored by Alliance for Clinical Trials in Oncology.
- RECRUITING
- Registry status
- NA
- Development phase
- 535 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase III trial compares the use of a digital chatbot enabled intervention to standard remote genetic services for increasing uptake of genetic counseling and testing among adolescents and young adult (AYA) cancer patients. Genetic testing for cancer predisposition syndromes has become standard evidence-based practice and can inform enhanced screening and risk reducing measures to reduce cancer morbidity and mortality. Despite this, many AYAs are not receiving recommended genetic counseling and testing. Offering remote telehealth services can address access barriers and chatbots and texting interventions could enhance patient outcomes and reduce provider and staff time. The use of a digital chatbot enabled intervention may be equally as effective as standard remote genetic services in AYA cancer patients undergoing genetic testing.
Primary Outcome
Defined as a binary outcome of whether an adolescent or young adult (AYA) underwent genetic counseling within 6 months post completion of the baseline survey. Will be compared between randomized arms using Cochran-Mantel-Haenszel (CMH) tests stratified by gender and a Bonferroni correction will be applied to control family-wise type I error.
Conditions Studied
Interventions
- OTHER Educational Intervention
- OTHER Genetic Testing
- OTHER Internet-Based Intervention
- OTHER Telemedicine
Study Locations (20)
California
- Mission Hope Medical Oncology - Arroyo Grande - Arroyo Grande
- Providence Saint Joseph Medical Center/Disney Family Cancer Center - Burbank
- Mercy Cancer Center - Carmichael - Carmichael
- Mercy San Juan Medical Center - Carmichael
- Mercy Cancer Center - Elk Grove - Elk Grove
- Mercy Cancer Center - Merced
- Providence Queen of The Valley - Napa
- Mercy Cancer Center - Rocklin - Rocklin
- Mercy Cancer Center - Sacramento - Sacramento
- Pacific Central Coast Health Center-San Luis Obispo - San Luis Obispo
- Mission Hope Medical Oncology - Santa Maria - Santa Maria
Alaska
- Anchorage Associates in Radiation Medicine - Anchorage
- Alaska Breast Care and Surgery LLC - Anchorage
- Alaska Oncology and Hematology LLC - Anchorage
- Alaska Women's Cancer Care - Anchorage
- Katmai Oncology Group - Anchorage
- Providence Alaska Medical Center - Anchorage
Arkansas
- Mercy Hospital Fort Smith - Fort Smith
- CARTI Cancer Center - Little Rock
Arizona
- Cancer Center at Saint Joseph's - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 535 participants |
| Start Date | 2025-12-10 |
| Est. Completion | 2029-04-30 |
| Phase | NA |
What NCT07091617 shows while recruiting
NCT07091617 is an interventional study that assigns participants to a tested intervention. The registered 535 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (62% lower).
The record links to 2 conditions, with Miscellaneous Neoplasm, NOS appearing as the primary indexed condition, and to 4 interventions - of which Educational Intervention is the first listed.
NCT07091617 names 20 study sites across 4 states, led by California, Alaska, Arkansas.
Frequently Asked Questions
What is clinical trial NCT07091617 about?
NCT07091617 is a clinical study titled "Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer". This phase III trial compares the use of a digital chatbot enabled intervention to standard remote genetic services for increasing uptake of genetic counseling and testing among adolescents and young adult (AYA) cancer patients. Genetic testing for cancer predisposition syndromes has become standard...
What is the current status of trial NCT07091617?
This trial is currently recruiting. It is a NA study. The enrollment target is 535 participants. The study started on 2025-12-10. Estimated completion is 2029-04-30.
What conditions does trial NCT07091617 study?
This clinical trial studies the following conditions: Miscellaneous Neoplasm, NOS, Non-Neoplastic Condition, Nos.
What interventions are being tested in trial NCT07091617?
The interventions under investigation include: Educational Intervention (OTHER), Genetic Testing (OTHER), Internet-Based Intervention (OTHER), Telemedicine (OTHER).
Who is sponsoring clinical trial NCT07091617?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07091617 being conducted?
This trial has 20 study locations across Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Miscellaneous Neoplasm, NOS
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07091617's enrollment target sits among peer trials
535 188th of 2000 higher than 1,813 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05614739 · 535 participants · Phase 1
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
- NCT04910685 · 534 participants · Phase 2
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
- NCT06128551 · 534 participants · Phase 1
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- NCT05880004 · 537 participants · NA
Developing a Support Application for Food Pantries (SAFPAS) to Improve Client Access to Healthy Foods & Enhance Emergency Preparedness
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI